Cassava Sciences distributes warrants to common shareholders; each 10 shares get 4 warrants exercisable at $33

FILANA THERAPEUTICS, INC.

Distribution of warrants to holders of record as of Dec 22, 2023, at ratio of 4 warrants per 10 common shares.
Each warrant allows purchase of one share at $33, plus a bonus of 0.5 additional shares if exercised before bonus expiry.
Warrants expire Nov 15, 2024; redeemable by company after Apr 15, 2024 at 1/10 of $0.01 per warrant.
Warrants expected to trade on Nasdaq under ticker SAVAW starting Jan 4, 2024.
Prospectus supplement filed to register 24,342,150 shares of common stock for issuance upon warrant exercise.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

FILANA THERAPEUTICS, INC. entered into Warrant Agreement with Computershare Inc. and Computershare Trust Company, N.A. valued at Warrants to purchase shares of Common Stock at an Exercise Price of $33.00 per Warrant, with a Bonus (effective 2024-01-03).

Action: entry
Counterparty: Computershare Inc. and Computershare Trust Company, N.A.
Value: Warrants to purchase shares of Common Stock at an Exercise Price of $33.00 per Warrant, with a Bonus
Effective: 2024-01-03

Exact text from the filing

On December 12, 2023, Cassava Sciences, Inc., a Delaware corporation (the " Company "), announced that the Board of Directors of the Company declared a distribution (the " Warrant Distribution ") to the holders of record of the Company's shares of common stock, par value $0.001 per share (the " Common Stock "), in the form of warrants to purchase shares of Common Stock (the " Warrants ").

View on SEC.gov

800 material agreements filed in the last 30 days. Browse all material agreements →

FILANA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-000209

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.